Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells

• Published in: BMC cancer Vol. 17; no. 1; p. 905
• Main Authors: Chang, Chia-Hsin, Liu, Wei-Ting, Hung, Hui-Chi, Gean, Chia-Yu, Tsai, Hong-Ming, Su, Chun-Lin, Gean, Po-Wu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 29.12.2017; BioMed Central; BMC
• Subjects: Cancer; Cancer stem cells; Combination therapy; Drug resistance; Drug therapy; Glioblastomas; Glioma; Growth; Minocycline; STAT3; Stem cell transplantation; Stem cells; Synergy; Minocycline; Synergy; Glioma; Cancer stem cells; Combination therapy; STAT3
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-017-3924-y

Glioma stem cells (GSCs) contribute to tumor recurrence and drug resistance. This study characterizes the tumorigenesis of CD133 cells and their sensitivity to pharmacological inhibition. GSCs from human U87 and rat C6 glioblastoma cell lines were isolated via magnetic cell sorting using CD133 as a cancer stem cell marker. Cell proliferation was determined using the WST-1 assay. An intracranial mouse model and bioluminescence imaging were used to assess the effects of drugs on tumor growth in vivo. CD133 cells expressed stem cell markers and exhibited self-renewal and enhanced tumor formation. Minocycline (Mino) was more effective in reducing the survival rate of CD133 cells, whereas CD133 cells were more sensitive to inhibition by the signal transducer and activator of transcription 3 (STAT3) inhibitor. Inhibition of STAT3 decreased the expression of CD133 stem cell markers. The combination of Mino and STAT3 inhibitor synergistically reduced the cell viability of glioma cells. Furthermore, this combination synergistically suppressed tumor growth in nude mice. The results suggest that concurrent targeting of different subpopulations of glioblastoma cells may be an effective therapeutic strategy for patients with malignant glioma.